|
Jul 17
|
Abeona Therapeutics Inc. (NASDAQ:ABEO) About To Shift From Loss To Profit
|
|
Jul 15
|
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
|
|
Jul 14
|
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
|
|
Jul 2
|
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
|
|
Jul 1
|
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
|
|
Jun 30
|
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
|
|
Jun 24
|
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
|
|
May 30
|
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
|
|
Oct 1
|
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 21
|
Institutional investors own a significant stake of 39% in Abeona Therapeutics Inc. (NASDAQ:ABEO)
|
|
Jun 21
|
Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO)
|
|
May 28
|
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
|
|
May 28
|
ABEO: BLA Resubmission in 2H24
|
|
May 16
|
Abeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
|
|
May 16
|
Q1 2024 Abeona Therapeutics Inc Earnings Call
|
|
May 15
|
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
|
|
May 3
|
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
|
|
Apr 25
|
ABEO: Receives CRL Based on Need for More CMC Information…
|
|
Apr 23
|
FDA rejects Abeona cell therapy, asks for more manufacturing data
|
|
Apr 22
|
Abeona Therapeutics Provides Regulatory Update on Pz-cel
|